生物制剂治疗银屑病对肾功能的影响

Effects of Biologic Therapy on Renal Function in the Treatment of Psoriasis

银屑病是一种常见的慢性炎症性皮肤病,既往研究表明,银屑病与肾损伤存在一定关联,慢性肾脏病是其共病之一。生物制剂作为一种新型治疗药物,已广泛应用于银屑病的治疗。临床试验及真实世界研究均表明,生物制剂治疗不合并肾损伤的银屑病患者在肾功能方面显示出良好的安全性。而针对合并肾损伤的银屑病患者,目前研究表明,生物制剂治疗对肾功能影响较小。但目前的研究以病例报告和小规模的回顾性研究为主,仍需多中心、大样本的研究进一步探讨生物制剂治疗在合并肾损伤的银屑病患者中的有效性及安全性。

Psoriasis is a common chronic inflammatory skin disease,and previous studies have shown a certain association between psoriasis and renal injury,with chronic kidney disease being one of its comorbidities.Biologic agents,as a novel therapeutic modality,have been widely used in its treatment.Clinical trials and real-world studies have shown that biologic agent therapy in psoriasis patients without concomitant renal injury demonstrates good safety in terms of renal function.Regarding psoriasis patients with renal injury,current studies suggest that biologic agent therapy has minimal impact on renal function.However,the existing research primarily consists of case reports and small-scale retrospective studies,and further investigations with multicenter and large sample sizes are still needed to explore the efficacy and safety of biologic agent therapy in psoriasis patients with renal injury.